- Home
- JGH vs PRQR Comparison
JGH vs PRQR Comparison
Compare JGH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JGH
- PRQR
- Stock Information
- Founded
- JGH 2014
- PRQR 2012
- Country
- JGH United States
- PRQR Netherlands
- Employees
- JGH N/A
- PRQR N/A
- Industry
- JGH Investment Managers
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- JGH Finance
- PRQR Health Care
- Exchange
- JGH Nasdaq
- PRQR Nasdaq
- Market Cap
- JGH 308.3M
- PRQR 309.5M
- IPO Year
- JGH N/A
- PRQR 2014
- Fundamental
- Price
- JGH $12.78
- PRQR $2.69
- Analyst Decision
- JGH
- PRQR Strong Buy
- Analyst Count
- JGH 0
- PRQR 5
- Target Price
- JGH N/A
- PRQR $7.60
- AVG Volume (30 Days)
- JGH 73.9K
- PRQR 605.4K
- Earning Date
- JGH 01-01-0001
- PRQR 11-07-2024
- Dividend Yield
- JGH 9.85%
- PRQR N/A
- EPS Growth
- JGH N/A
- PRQR N/A
- EPS
- JGH N/A
- PRQR N/A
- Revenue
- JGH N/A
- PRQR $20,506,357.00
- Revenue This Year
- JGH N/A
- PRQR $235.11
- Revenue Next Year
- JGH N/A
- PRQR N/A
- P/E Ratio
- JGH N/A
- PRQR N/A
- Revenue Growth
- JGH N/A
- PRQR 306.68
- 52 Week Low
- JGH $10.36
- PRQR $1.61
- 52 Week High
- JGH $12.85
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- JGH 32.36
- PRQR 37.43
- Support Level
- JGH $12.65
- PRQR $2.48
- Resistance Level
- JGH $13.38
- PRQR $2.83
- Average True Range (ATR)
- JGH 0.12
- PRQR 0.28
- MACD
- JGH -0.06
- PRQR -0.06
- Stochastic Oscillator
- JGH 17.81
- PRQR 26.01
About JGH Nuveen Global High Income Fund of Beneficial Interest
Nuveen Global High Income Fund operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of current income. Its securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.